CLIA Waiver Sign-Off May Return To FDA – OIVD’s St. Pierre
This article was originally published in The Gray Sheet
Executive Summary
HHS may decide by Nov. 1 whether to shift the delegation authority for CLIA waivers to FDA, OIVD Deputy Director for New Device Evaluation Donald St. Pierre stated at the Regulatory Affairs Professionals Society's annual conference in Baltimore Oct. 22